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We  brieﬂy  review  the role of  astrocytes  in  brain  function.
We  review  the  main  pathways  in  astrocytic  dysfunction.
We  focus  on  astroglial-speciﬁc  targets  for clinical  management  of  neurodegenerative  disorders.
We  describe  the  usefulness  of a  systems  biology  approach  in  drug  discovery  for  neurodegenerative  disorders.
 r  t i  c  l  e  i  n  f  o
rticle history:
eceived 22 September 2013
eceived in revised form 8 January 2014
ccepted 13 January 2014
a  b  s  t  r  a  c  t
Chronic  neurodegenerative  diseases  represent  major  unmet  needs  for therapeutic  interventions.
Recently,  the  neurocentric  view  of brain  function  and  disease  has  been  challenged  by  a great  number
of  evidence  supporting  the physiopathological  potential  of  neuroglia.  Astrocytes,  in particular,  play  a
pivotal  role  in  brain  homeostasis  as they  actively  participate  in neuronal  metabolism,  synaptic  plastic-eywords:
eactive astrogliosis
rain  homeostasis
eurotrophins
europrotection
ystems biology
ity  and  neuroprotection.  Furthermore,  they  are  intrinsic  components  of brain  responses  to toxic  and
traumatic  insults  through  complex  processes  involving  several  molecular  and  functional  alterations  that
may  lead  to  disruption  of  brain  homeostasis  and  connectivity.  This  review  provides  a brief  overview
of  current  knowledge  of astrocyte  functions  in the  brain,  and  focuses  on  some  glial-speciﬁc  pathways
involved  in  astrocytic  dysfunction  that might  be effective  therapeutic  targets  for  clinical  management  of
neurodegenerative  disorders.©  2014  The  Authors.  Published  by  Elsevier  Ireland  Ltd.  
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. Introduction
Astrocytes are multifunctional cells that might well be con-
idered the “cornerstone” of brain cytoarchitecture and function.
n addition to their trophic and structural role, astrocytes are
ynamic components of brain connectivity and function. The con-
ept of “tripartite synapse” encompasses the fundamental role
f astrocytes in synaptic function and plasticity, which involves
aintenance of homeostatic balance of neurotransmitters and
ons, as well as regulation of blood ﬂow and neuronal energy
etabolism. In addition, they participate to brain responses to
oxic and traumatic insults through a complex process (reactive
strogliosis) that involves morphological and functional changes
ncluding hypertrophy, upregulation of intermediate ﬁlaments,
uch as GFAP, and increased proliferation [35,40]. Reactive astro-
ytes also release cytokines and many other factors that mediate
nﬂammatory responses and remodeling processes [24], thus
laying both beneﬁcial and detrimental roles in brain pathol-
gy.
In this review we will highlight how astrocytes alterations
uring neuroinﬂammation inﬂuence brain integrity, thus compro-
ising synaptic homeostasis and function. We  will then focus on
olecular mechanisms of astrogliosis that can be potential targets
or drug development to restore brain function in neurodegenera-
ive diseases.
.  Astrocytes in synaptic function
At synaptic level, astrocytes express functional neurotrans-
itter receptors (Fig. 1) and release several neurotransmitters,
ncluding glutamate, GABA, ATP and d-serine through Ca2+-
ependent exocytosis, thereby modulating synaptic strength and
fﬁcacy at excitatory and inhibitory synapses. Moreover, astro-
ytes possess neurotransmitter transporters for glutamate (EAAT1
nd EAAT2, in rodents known as GLAST and GLT-1) (Fig. 1),
ABA and glycine, thus playing a crucial role in neurotransmit-
er homeostasis. At glutamatergic synapses, astrocytic glutamate
ptake is the main route for glutamate removal from synaptic
left to avoid its potential excitotoxicity [38]. Recovery of gluta-
ate also occurs through vesicular glutamate transporters (vGLUT)
33] and the glutamate-glutamine shuttle system (Fig. 1): gluta-
ate is converted to the non-toxic glutamine and shuttled back to
resynaptic neurons to reconstitute neurotransmitter pools. The
ystine-glutamate antiporter system (xCT) [26] is also function-
lly related to the role of astrocytes in regulating extracellular
lutamate and supplying cystine for neuronal GSH homeostasis.
elevant to both synaptic transmission and neuroprotection is then
he control of K+ homeostasis by inward rectifying K+ channels
Kir-channels) (Fig. 1).
Other  crucial functions of astrocytes include blood–brain bar-
ier (BBB) formation and metabolic support: through their endfeet
ontacting capillary endothelial cells, astrocytes are active compo-
ents of the BBB properties and regulate cerebral blood ﬂow and
etabolic supply in response to neuronal activity (neurometabolicoupling) [27]. Metabolic support to neurons is provided through
he astrocyte-neuron lactate shuttle: lactate is released by astro-
ytes and taken up into neurons for their energy metabolism after
ts conversion to pyruvate (Fig. 1). . . . .  .  . .  . . . . . .  . . . . .  . .  .  . . . . . .  .  . . . . . . .  .  . . .  . . . .  . .  .  .  . . . .  .  .  . . . . .  . . .  .  .  .  . . . .  .  . . . . .  63
3.  Astrogliosis and neurological disorders
Over the last two  decades, the neurocentric view of brain
function and disease has been challenged by the emerging evi-
dence of the physiopathological potential of neuroglia [24,40].
Current knowledge of neuropathological processes indicates that
early stages of disease are associated with the activation of com-
mon inﬂammatory pathways, involving microglia and astrocytes
activation, and the release of pro-inﬂammatory cytokines and
other inﬂammatory mediators that regulate astrocytic hypertro-
phy and proliferation. Evidence of neuroinﬂammatory processes
has been found in several neurological disorders, such as ischemia,
spinal cord injury (SCI) and psychiatric/mood disorders [34,42],
as well as in neurodegenerative diseases including Alzheimer’s
disease (AD), Parkinson’s disease (PD), amyotrophic lateral scle-
rosis (ALS), spinocerebellar ataxia type 1 (SCA1), Huntington’s
disease (HD) and multiple sclerosis (MS) [revised in Ref. [24]].
Our recent studies also indicate that glial activation after periph-
eral nerve injury is an important component of the neuropathic
pain syndrome, as revealed by microglial activation and increased
GFAP expression in the spinal cord [11–14] and supraspinal level
[28].
Biochemical and structural changes of astrocytes during neu-
roinﬂammation represent a physiological response to CNS injury
to minimize and repair the initial damage. Nevertheless, sustained
inﬂammatory responses might be driven by positive feedback loops
between microglia and astrocytes (Fig. 1) under conditions of
severe and/or prolonged brain insults, thus providing detrimen-
tal signals that can compromise astrocytic and neuronal functions
and lead to chronic neuroinﬂammation [24,40].
Accordingly, in our model of peripheral nerve injury, glial
activation was paralleled by several modiﬁcations including: (i)
decreased GLT-1 levels; (ii) alteration of vesicular transporters of
glutamate (vGLUT) and GABA (vGAT); (iii) a functional block of the
xCT system, most likely triggered by extracellular glutamate accu-
mulation; (iv) decreased GSH content; and (v) alteration of nerve
growth factor (NGF) and neurotrophin receptors levels [11–13].
Modiﬁcations of synaptic components appeared to be sustained
by a calpain I-dependent process, while alteration of pro-NGF/NGF
ratio was  functionally related to activation of matrix metallopro-
teinases (MMPs) (Fig. 1). Similar biochemical alterations have been
observed in other neurological models of diseases and suggest a
general failure of normal astrocytic functions in brain homeostasis
and neuroprotection, thus determining mechanisms of “maladap-
tive plasticity” [12,13,15,28].
4.  Reactive astrocytes as potential therapeutic targets
Based  on the pathogenetic role of astrocytic dysfunction, the
strategy to restore or enhance normal astrocytic functions might
be an appealing way to promote neuroprotection in a variety of
brain disorders.
Current understanding of the precise contribution of reac-
tive astrogliosis in disease progression has been fostered by the
development of transgenic animals enabling the manipulation of
astrocyte-speciﬁc proteins and pathways. Interestingly, different
types of transgenic models indicate that the overall impact of reac-
tive astrogliosis is beneﬁcial and neuroprotective, in particular
A.M. Colangelo et al. / Neuroscience Letters 565 (2014) 59–64 61
Fig. 1. Schematic representation of a tripartite synapse showing some of the pharmacological targets in astrocytic dysfunction: molecular alterations induced by cytokines
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ssue.
uring early stages of disease. In fact, conditional ablation of prolif-
rating astrocytes leads to increased inﬂammation and increased
euronal vulnerability in models of SCI and experimental autoim-
une encephalitis (EAE) [40]. Nevertheless, astrocytic function in
europrotection is greatly compromised during chronic neuroin-
ammation. New perspectives for therapeutic approaches include
he replacement of dysfunctional astrocytes or pharmacological
reatments that speciﬁcally target detrimental signaling pathways
hile preserving their neuroprotective functions.
. Cell-based therapeutic strategies
Different innovative approaches have been developed in
egenerative medicine to promote neuroprotection. For instance,
ransplantation of mouse or human astrocytes derived from
lial-restricted progenitors (GRP) was found to promote axonal
egeneration and functional recovery following SCI. Other studies
lso showed that mesenchimal stem cells injected into the spinal
ord were able to migrate to the lesioned area, differentiate into
strocytes and exert neuroprotection by reducing microglial acti-
ation and normalizing GLT-1 levels [25]. Cell grafting strategies
ave been successfully employed in different models of neurode-
enerative diseases, such as PD, ALS and HD. For instance, grafting
f astrocytes overexpressing brain-derived neurotrophic factor
BDNF) under control of the GFAP promoter was found to exert
europrotection in a model of HD [23]. Recently, the possibility
o obtain astrocytes by reprogramming induced pluripotent stem
ells may  also represent a new strategy for the replacement of dam-
ged astrocytes, although further experimental studies are needed
o evaluate therapeutic and side effects of cell therapy.
.  Targeting inﬂammation-related signalingInﬂammatory processes are the hallmark of both acute and
hronic neurodegenerative diseases. Glial reaction involves acti-
ation of receptors, such as Toll-like receptors (TLR), transcription
actors (NF-kB, Nrf2, AP-1, etc.) and signaling molecules (p38MAPK,tion (oATP); alteration of NGF synthesis/degradation (BB14 and MMPs inhibition).
bout these mechanisms can be found in the text and in other reviews of this special
JNK,  JAK/STAT3, etc.) of common inﬂammatory pathways (Fig. 1),
as well as alteration of protein expression (GFAP, vimentin,
aminoacid transporters, receptors, etc.) and enzymes, like cycloxy-
genases (COX2), nitric oxide synthase (NOS), MMPs, etc. [revised
in Ref. [24]]. For instance, TLRs are associated with the activation
of microglia and astrocytes by amyloid- and the downstream
inﬂammatory response in AD models. Therefore, molecules that
antagonize or modulate sensors (TLR, etc.), transducers (NF-kB,
AP-1, etc.) and effectors (TNF-, COX-2, etc.) of the inﬂammatory
response may  represent a new prospective for disease-modifying
therapies.
Besides the novel concept of a peripheral origin of neu-
roinﬂammation based on bi-directional gut-brain communication
[29], evidence of the role of inﬂammation in neurodegenerative
processes is provided by epidemiological studies showing that ele-
vated plasma concentrations of TNF-, IL-6 and other cytokines
correlate with increased PD risk [10]; whereas, chronic use of anti-
inﬂammatory drugs (like NSAIDs) reduces the risk of PD and AD
[16]. Besides inhibiting COX-1/2 activity and prostaglandin produc-
tion, other molecular targets of NSAIDs include NF-B, AP-1, NOS,
PPAR and secretases [4].
Nuclear translocation of NF-B in reactive astrocytes was shown
to mediate glial proliferation and inﬂammatory responses (Fig. 1).
Indeed, mice expressing a constitutively active form of IB under
control of the GFAP promoter exhibit reduced inﬂammation and
increased functional recovery following SCI or EAE [6]. Efﬁcient
inhibition of NF-B can also be achieved by antioxidant molecules,
like ﬂavonoids. Many experimental studies are currently testing the
beneﬁcial effects of antioxidants, based on the hypothesis that pro-
oxidant environments, such as the inﬂammatory milieu, can favor
the formation of toxic protein aggregates of amyloid-, SOD1, etc.
The JAK/Stat pathway (Fig. 1) is another transducer of inﬂam-
matory signals mediated by growth factors and cytokines (IL-6,
CNTF, EGF and TGF-): genetic deletion or inhibition of STAT3
was able to reduce all aspects of reactive astrogliosis (upregula-
tion of GFAP, astrocytes proliferation and migration); however, as
a result of impaired glial scar formation, mice with conditional
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eletion (Cre–loxP system) of STAT3 in astrocytes displayed
ncreased inﬂammation [34].
JNK and p38MAPK signaling pathways (Fig. 1) were also found
o be relevant to reactive gliosis in response to a variety of
ytokines and pathogenetic stimuli. Several MAPK inhibitors have
een characterized in vitro and in animal models. Among them,
he BIRB-796-BS molecule developed by Boehringer Ingelheim
harmaceuticals was found to prevent LPS-induced cytokines pro-
uction [7], whereas SB203580 reduced the expression of iNOS,
NF-, IL-1 and COX2 in a model of focal ischemia by middle
erebral artery occlusion resulting in reduced infarct volume and
eurological deﬁcits [36].
Molecular  mediators and receptors of inﬂammatory processes
re also the therapeutic target of all drugs currently used
n MS  (humanized antibodies against 41 integrin, CD20 B-
ymphocytes and TNF-) to reduce neuroinﬂammation and the
bnormal activity of the immune system. Interestingly, the anti-
nﬂammatory activity of -lactam antibiotics also seems to involve
he regulation of astrocytic function: ceftriaxone was found to exert
europrotection in animal models of ALS by stimulating the expres-
ion of GLT-1 [39].
.  Glutamate metabolism and excitotoxicity
The scavenging activity of astrocytes is crucial in regulating
xcessive levels of glutamate, K+ and other ions. GLT-1 levels
ecline in different models of neurodegenerative diseases, such as
D, ALS and HD, suggesting a correlation between reactive gliosis
nd accumulation of excitotoxic levels of glutamate [39]. Loss or
ysfunction of astrocytic glutamate transporters were also found in
poradic forms of ALS and HD patients at early stages of the disease
37].
Currently, riluzole is the only FDA-approved drug for the treat-
ent of ALS, though it prolongs the life of ALS patients by only
 months [30]. A major action of riluzole is the inhibition of gluta-
ate release from presynaptic neurons, but it also blocks glutamate
ctivity on postsynaptic terminals by non-competitive blockade
f NMDA receptors (Fig. 1). Recently, riluzole was also found to
nhance astrocytic glutamate uptake by upregulating GLT-1 levels
nd activity [9]. Interestingly, however, neuroprotection by riluzole
eems to be also related to its capability to stimulate astrocytic syn-
hesis of NGF, BDNF and GDNF [32]. Increased levels of BDNF and
GF-1 were also detected in the serum of patients treated with
iluzole [41].
Excitotoxic levels of glutamate during neuroinﬂammation are
lso contributed by astrocytes through Ca2+-dependent secretory
athways following intracellular [Ca2+] rise (Fig. 1). Several astro-
ytes receptors are coupled to Ca2+-dependent signalings that can
ead to glutamate release: prostaglandins (like PGE2), purinergic
eceptors (Fig. 1), bradykinin and other GPCRs acting through Ca2+
obilization from IP3R-sensitive intracellular stores [1].
In  addition to its role as energy source, ATP is important in
odulating glia-glia and glia-neuron communication [revised in
ef. [21]]. Purinergic receptor stimulation by ATP (released from
amaged cells) can modulate several mechanisms of neuroinﬂam-
atory pathways, such as synthesis of cytokines, upregulation
f COX-2, production of PGE2, proliferation, glutamate and GABA
elease, impairment of glutamate uptake, decreased expres-
ion/activity of glutamine synthetase (GS), increase of iNOS activity
nd NO production (Fig. 1). Therefore, these receptors might be well
onsidered a functional link between inﬂammatory responses and
ltered glutamate and GABA transmission through the activation
f multiple intracellular pathways including GPCRs/IP3R/DAG/PKC,
PCRs/AC/cAMP/PKA, MAPK, JNK or p38MAPK. Although the
any activities of both ionotropic (P2X) and metabotropic (P2Y)e Letters 565 (2014) 59–64
receptors  is not fully understood, purinergic receptors are impor-
tant modulators of reactive gliosis, in particular in chronic
neurodegenerative pathologies, thus representing a useful thera-
peutic target to modulate glial reaction and disease progression.
8.  Targeting astrogliosis by neurotrophins and
neurotrophin-derived drugs
In addition to their crucial role in synaptic function and
inﬂammatory responses, astrocytes provide trophic and metabolic
support. Among neurotrophin family members, NGF and BDNF
are the most relevant molecules in brain development and func-
tion, and it is generally recognized that their age-related decreased
availability play a crucial role in the pathophysiology of neurode-
generative disorders.
All  neurotrophins are secreted on demand by astrocytes as pro-
neurotrophins, proteolytically cleaved to mature neurotrophins in
the synaptic cleft and rapidly degraded (Fig. 1). Precursors and
mature neurotrophins can differently interact with tyrosine kinase
(Trk) and p75NTR receptors, which can have opposing actions in
modulating neuron death/survival, synaptic plasticity and glial pro-
liferation [17,20]. Thus, neurotrophin activity is essentially linked
to a dynamic balance between their maturation and degradation
processes: NGF/pro-NGF ratio, for instance, is regulated by the tis-
sue plasminogen activator (tPA)-plasmin-MMP-9 system (Fig. 1)
[19].
Alteration of neurotrophin maturation/degradation processes
and increased proNGF and proBDNF levels are believed to trigger
neuronal vulnerability in several neurodegenerative diseases, such
as AD and ALS, by a p75-mediated mechanism [19,20]. On the other
hand, NGF interaction with p75 was shown to reduce astrocytic
proliferation (Fig. 1) [17], thus exhibiting an anti-gliosis activity.
We  also found that following peripheral nerve injury, glial acti-
vation and synaptic changes were paralleled by increased MMPs
activity and altered NGF/pro-NGF and receptors levels [11–13].
Interestingly, these alterations were reversed by i.t. administration
of NGF or GM6001 (Fig. 1), a generic MMP  inhibitor [11–14]. Overall,
these ﬁndings are consistent with a model in which NGF and other
neurotrophins are essential in maintaining synaptic homeostasis
and neuroprotection by establishing a strict correlation between
astrocytic dysfunction and aberrant balance between NGF synthe-
sis and degradation [15]. Furthermore, it should be recalled the
essential role of NGF in supporting neuronal survival by modulating
mitochondrial function (Fig. 1) [5].
Recently, small molecules activating speciﬁc neurotrophin
receptors represent a valid alternative to the poor pharmacokinetic
properties of neurotrophin-based therapies. This strategy has been
employed to construct small functional mimetics of NGF, BDNF
and NT-3 endowed with agonist or antagonist activity for Trks or
p75 receptors [8,43]. Some of these molecules were found to be
effective in models of cholinergic dysfunction, mood disorders and
glaucoma [8]. We  recently developed the NGF-like peptide, BB14,
which displayed a strong TrkA agonist activity both in vitro and in
models of peripheral nerve injury. Moreover, BB14 reduced reac-
tive gliosis and neuropathic behavior to same extent as the native
NGF molecule, suggesting that it might be suitable for therapeutic
applications in neurological conditions characterized by reactive
gliosis [13–15].
9.  A systems biology approach in drug discovery for
neuro-glial network repairThe functional link between all components of reactive glio-
sis (excitotoxicity, decreased neuronal metabolism and antioxidant
properties, alteration of neurotrophins metabolism/signaling, and
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mpaired synaptic plasticity) is indicative of the impact that
lterations of the complex neuro-glial network have on disease pro-
ression. This implies that effective neuroprotection of the whole
ystem should take into account both the complex intracellular
rosstalks (neuronal, astroglial, etc.) and how they inﬂuence proper
eciprocal interactions, communication and function.
A  comprehensive understanding of mechanisms contributed
y astrocytes appears to be relevant for development of tar-
eted therapies for clinical management of neurodegenerative
isorders. Given the complexity of neuro-glial networks in CNS
omeostasis and function, a systems biology approach of neu-
odegeneration [2,18] might be necessary to obtain a whole
icture of the glia-neuron interplay in synaptic function, and how
hanges of metabolic ﬂuxes might inﬂuence the complex interac-
ions between neuronal and glial compartments and lead to the
tructural/functional modiﬁcations underlying neuro-glial rear-
angements during the degeneration process.
As it is well known, systems biology considers the function
f complex biological processes as system-level properties gener-
ted by the interactions of large molecular networks that underlie
ach given biological function, which is investigated by integra-
ion of molecular analyses and computational methods [3]. The ﬁrst
tep, therefore, is to identify the molecular network that underlies
eurodegeneration. Two recent reports have opened the way by
aking publicly available maps of pathways for AD and PD [22,31].
t the moment, the AD map  is composed by 1347 molecules and
070 reactions in neurons, BBB, pre-synaptic and post-synaptic
eurons, astrocytes and microglial cells. The PD map  currently has
285 elements and 989 reactions: it is restricted to dopaminer-
ic neurons in the sustantia nigra, whose progressive degeneration
eavily contributes to the more relevant clinical motor symptoms
f PD. Both AD and PD maps are open to the research community
or utilization and improvement.
Key questions raised by these maps are: (1) how to identify,
mong the intricate web  of thousand molecules, the crucial steps
hat are essential in supporting the insurgence of the pathology;
nd (2) how to discriminate the one or few molecular targets that,
hen hit by a drug, will substantially and permanently ameliorate
he clinical condition of the patients.
A similar problem is faced for cancer and attempts are made to
isassemble the phenotype of cancer cells in a number of system-
evel properties and then to apply multilevel modeling [18] to
nvestigate for each property (or function) its general organizing
rinciples. The next step is to focus on the molecular level trying to
onstruct dynamic molecular mathematical models able to clarify
he mechanism of any given speciﬁc feature [3].
The availability of AD and PD maps may  facilitate this approach
or a system-level analysis of neurodegeneration which, in the view
resented in this paper, will consider as very relevant the role of
strogliosis both in preventing and, above a threshold level, in pro-
oting neurodegeneration.
0.  Conclusions and future perspectives
Molecular dissection of neurological and neurodegenerative
isorders strongly indicates that reactive astrogliosis is an intrin-
ic component of the complex mechanisms that, initially meant
o be protective against toxic stimuli, above a threshold level turn
nto maladaptive responses that can compromise synaptic homeo-
tasis and function, thus amplifying the pathology. Based on this
nowledge, it is intuitive that effective neuroprotection might be
chieved by preventing astrocytic dysfunction and their detrimen-
al responses, at the same time preserving their protective and
rophic/metabolic functions. Although many glial pathways have
een identiﬁed as potential therapeutic targets, it is clear that more
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work is needed to obtain a comprehensive understanding of the
entire process, crucial steps and speciﬁc time windows for effective
therapeutic interventions. The drug discovery process might be fos-
tered by a systems biology approach to disassemble the astrogliosis
phenotype in its components and apply multilevel modeling to
identify key molecular targets. At the same time, given that cell-
therapy strategies to replace de-regulated/dysfunctional astrocytes
by transplantation still hold great limitations, more efforts should
be made to apply novel biotechnological approaches to trans-
late current knowledge of astrocytes into effective therapeutic
molecules.
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